Lithium: An Old Drug for New Therapeutic Strategy for Alzheimer’s Disease and Related Dementia
Neurodegenerative Diseases · 2023 · 23 (1-2) · 1-12
DOI: 10.1159/000533797 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Neurodegenerative Diseases, online erschienen am 04.09.2023. Verfasst von Seong Sool Shim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognition Disorders. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 146 Literaturangaben. Gefördert von: BLRD VA.
Themen: Demenz
Abstract (Originalsprache)
Background: Although Alzheimer’s disease (AD) is the most common form of dementia, the effective treatment of AD is not available currently. Multiple trials of drugs, which were developed based on the amyloid hypothesis of AD, have not been highly successful to improve cognitive and other symptoms in AD patients, suggesting that it is necessary to explore additional and alternative approaches for the disease-modifying treatment of AD. The diverse lines of evidence have revealed that lithium reduces amyloid and tau pathology, attenuates neuronal loss, enhances synaptic plasticity, and improves cognitive function. Clinical studies have shown that lithium reduces the risk of AD and deters the progress of mild cognitive impairment and early AD. Summary: Our recent study has revealed that lithium stabilizes disruptive calcium homeostasis, and subsequently, attenuates the downstream neuropathogenic processes of AD. Through these therapeutic actions, lithium produces therapeutic effects on AD with potential to modify the disease process. This review critically analyzed the preclinical and clinical studies for the therapeutic effects of lithium on AD. We suggest that disruptive calcium homeostasis is likely to be the early neuropathological mechanism of AD, and the stabilization of disruptive calcium homeostasis by lithium would be associated with its therapeutic effects on neuropathology and cognitive deficits in AD. Key Messages: Lithium is likely to be efficacious for AD as a disease-modifying drug by acting on multiple neuropathological targets including disruptive calcium homeostasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, USA.
- Mental Health Service Line, Department of Veteran's Affair, Atlanta VA Medical Center, Decatur, Georgia, USA.
- Department of Veteran's Affair, Center for Visual and Neurocognitive Rehabilitation, Atlanta VA Medical Center, Decatur, Georgia, USA.
- Department of Neurosurgery, Emory University School of Medicine, Atlanta, Georgia, USA.
- Department of Anesthesiology, Emory University School of Medicine, Atlanta, Georgia, USA.
Förderung
- BLRD VA
Zitieren
APA
Shim, S. S., Berglund, K., & Yu, S. P. (2023). Lithium: An Old Drug for New Therapeutic Strategy for Alzheimer’s Disease and Related Dementia. Neurodegenerative Diseases, 23(1-2), 1-12. https://doi.org/10.1159/000533797
Vancouver
Shim SS, Berglund K, Yu SP. Lithium: An Old Drug for New Therapeutic Strategy for Alzheimer’s Disease and Related Dementia. Neurodegenerative Diseases. 2023;23(1-2):1-12. doi:10.1159/000533797
BibTeX
@article{Shim2023,
author = {Shim, Seong Sool and Berglund, Ken and Yu, Shan Ping},
title = {Lithium: An Old Drug for New Therapeutic Strategy for Alzheimer’s Disease and Related Dementia},
journal = {Neurodegenerative Diseases},
year = {2023},
volume = {23},
number = {1-2},
pages = {1--12},
doi = {10.1159/000533797}
}
EUVIMED